Patents by Inventor Douglas E. Brenneman

Douglas E. Brenneman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220257620
    Abstract: The invention relates to compositions containing certain phosphatidylcholines containing long chain polyunsaturated fatty acids in the sn-1 position or both the sn-1 and sn-2 positions as a neuroprotective agent, and further to treating or preventing oxidative stress in a neuronal tissue with such compositions.
    Type: Application
    Filed: June 26, 2020
    Publication date: August 18, 2022
    Inventors: Douglas E. BRENNEMAN, William A. KINNEY, Jason CLEMENT, Dean PETKANAS
  • Patent number: 10004722
    Abstract: Pharmaceutical compositions of the invention include novel functionalized 1,3-benzenediols having a disease-modifying action in the treatment of hepatic encephalopathy and related conditions. Pharmaceutical compositions of the invention further include novel neuroprotective agents.
    Type: Grant
    Filed: February 20, 2017
    Date of Patent: June 26, 2018
    Assignee: KANNALIFE SCIENCES, INC.
    Inventors: Douglas E. Brenneman, William Alvin Kinney, Mark McDonnell, Dean Petkanas
  • Publication number: 20170157097
    Abstract: Pharmaceutical compositions of the invention include novel functionalized 1,3-benzenediols having a disease-modifying action in the treatment of hepatic encephalopathy and related conditions. Pharmaceutical compositions of the invention further include novel neuroprotective agents.
    Type: Application
    Filed: February 20, 2017
    Publication date: June 8, 2017
    Inventors: Douglas E. BRENNEMAN, William Alvin KINNEY, Mark MCDONNELL, Dean PETKANAS
  • Patent number: 9611213
    Abstract: Pharmaceutical compositions of the invention include novel functionalized 1,3-benzenediols having a disease-modifying action in the treatment of hepatic encephalopathy and related conditions. Pharmaceutical compositions of the invention further include novel neuroprotective agents.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: April 4, 2017
    Assignee: KANNALIFE SCIENCES, INC.
    Inventors: Douglas E Brenneman, William Alvin Kinney, Mark McDonnell, Dean Petkanas
  • Publication number: 20160311769
    Abstract: Pharmaceutical compositions of the invention include novel functionalized 1,3-benzenediols having a disease-modifying action in the treatment of hepatic encephalopathy and related conditions. Pharmaceutical compositions of the invention further include novel neuroprotective agents.
    Type: Application
    Filed: January 9, 2015
    Publication date: October 27, 2016
    Inventors: Douglas E Brenneman, William Alvin Kinney, Mark McDonnell, Dean Petkanas
  • Patent number: 8609849
    Abstract: Pharmaceutical compositions of the invention include hydroxylated sulfamide derivatives having a disease-modifying action in the treatment of diseases associated with excitotoxicity and accompanying oxidative stress that include epilepsy, Alzheimer's disease, and any neurodegenerative disease involving glutamate toxicity.
    Type: Grant
    Filed: November 29, 2011
    Date of Patent: December 17, 2013
    Assignees: Fox Chase Chemical Diversity Center, Inc., Advanced Neural Dynamics, Inc.
    Inventors: Garry Robert Smith, Douglas E. Brenneman, Allen B. Reitz, Yan Zhang, Yanming Du
  • Publication number: 20130253022
    Abstract: Pharmaceutical compositions of the invention include fluorinated sulfamide derivatives having a disease-modifying action in the treatment of diseases associated with excitotoxicity and accompanying oxidative stress that include epilepsy, Alzheimer's disease, Parkinson's disease, Huntington's disease, heavy metal toxicity and any neurodegenerative disease involving glutamate toxicity.
    Type: Application
    Filed: November 18, 2011
    Publication date: September 26, 2013
    Applicants: FOX CHASE CHEMICAL DIVERSITY CENTER, INC., ADVANCED NEURAL DYNAMICS, INC.
    Inventors: Garry Robert Smith, Douglas E. Brenneman, Allen B. Reitz, Yan Zhang, Yanming Du
  • Patent number: 7863247
    Abstract: The invention relates to methods for reducing a condition associated with fetal alcohol syndrome in a subject who is exposed to alcohol in utero with an ADNF polypeptide (e.g, ADNF I polypeptides, ADNF III polypeptides, or mixtures of ADNF I and ADNF III polypeptides). In one embodiment, the present invention relates to methods for reducing a condition associated with fetal alcohol syndrome in a subject who is exposed to alcohol in utero with a mixture of ADNF I and ADNF III polypeptides. The present invention further relates to methods for reducing neuronal cell death by contacting neuronal cells with a mixture of ADNF I and ADNF III polypeptides. Still further, the present invention relates to a pharmaceutical composition comprising a mixture of ADNF I and ADNF III polypeptides.
    Type: Grant
    Filed: March 10, 2000
    Date of Patent: January 4, 2011
    Assignee: Ramot-University Authority for Applied Research and Development Ltd.
    Inventors: Douglas E. Brenneman, Catherine Y. Spong, Illana Gozes, Merav Bassan, Rachel Zamostiano
  • Publication number: 20090247457
    Abstract: This invention relates to Activity Dependent Neurotrophic Factor I complex (ADNF I complex) and polypeptides of this complex, which produce their neurotrophic effects through multiple proteases intrinsic to the ADNF I complex. The invention also relates to pharmaceutical compositions comprising ADNF I complex polypeptides, as well as methods for reducing neuronal cell death in vitro and in vivo, methods for treating oxidative stress in a patient, methods for reducing a condition associated with fetal alcohol syndrome in a subject, and methods of enhancing learning and memory both pre- and post-natally, all of which methods use the ADNF I complex polypeptides of the invention.
    Type: Application
    Filed: August 25, 2008
    Publication date: October 1, 2009
    Applicants: SECRETARY OF THE DEPTARTMENT OF HEALTH AND HUMAN SERVICES, RAMOT AT TEL-AVIV UNIVERSITY
    Inventors: DOUGLAS E. BRENNEMAN, RAQUEL CASTELLON, CATHERINE Y. SPONG, JANET M. HAUSER, IIIANA GOZES
  • Publication number: 20090124543
    Abstract: The present invention relates generally to Activity Dependent Neurotrophic Factor III (ADNF III), also known as Activity Dependent Neuroprotective Protein (ADNP). More particularly, the present invention relates to nucleic acid sequences encoding ADNF III polypeptides; ADNF III polypeptides encoded by such nucleic acid sequences; antibodies to ADNF III polypeptides; and methods of using such ADNF III polypeptides for the treatment of neurological deficiencies and for the prevention of cell death associated with (1) gp120, the envelope protein from HIV; (2) N-methyl-D-aspartic acid (excito-toxicity); (3) tetrodotoxin (blockage of electrical activity); and (4) ?-amyloid peptide, a substance related to neuronal degeneration in Alzheimer's disease.
    Type: Application
    Filed: August 13, 2007
    Publication date: May 14, 2009
    Applicants: The Govt. of the U.S.A., as represented by the Secretary of the Dept. of Health & Human Services, Ramot at Tel-Aviv University Ltd.
    Inventors: Illana Gozes, Douglas E. Brenneman, Merav Bassan, Rachel Zamostiano
  • Patent number: 7427590
    Abstract: This invention relates to Activity Dependent Neurotrophic Factor I complex (ADNF I complex) and polypeptides of this complex, which produce their neurotrophic effects through multiple proteases intrinsic to the ADNF I complex. The invention also relates to pharmaceutical compositions comprising ADNF I complex polypeptides, as well as methods for reducing neuronal cell death in vitro and in vivo, methods for treating oxidative stress in a patient, methods for reducing a condition associated with fetal alcohol syndrome in a subject, and methods of enhancing learning and memory both pre- and post-natally, all of which methods use the ADNF I complex polypeptides of the invention.
    Type: Grant
    Filed: September 12, 2002
    Date of Patent: September 23, 2008
    Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, Ramot at Tel-Aviv University, Ltd.
    Inventors: Douglas E. Brenneman, Raquel Castellon, Catherine Y. Spong, Janet M. Hauser, Illana Gozes
  • Publication number: 20080194488
    Abstract: This invention provides an ADNF polypeptide comprising an active core site, the active core site comprising at least one D-amino acid. The invention also provides a pharmaceutical composition comprising an ADNF polypeptide comprising an active core site, the active core site comprising at least one D-amino acid. In particular, the pharmaceutical composition of the invention is orally active. The invention further provides methods for reducing neuronal cell death, methods for reducing oxidative stress, and methods for reducing a condition associated with fetal alcohol syndrome using the ADNF polypeptides and the pharmaceutical compositions of the invention.
    Type: Application
    Filed: April 14, 2008
    Publication date: August 14, 2008
    Applicants: National Institute of Health, Ramot at Tel-Aviv University Ltd.
    Inventors: Illana Gozes, Albert Pinhasov, Eliezer Giladi, Douglas E. Brenneman, Catherine Y. Spong
  • Patent number: 7384908
    Abstract: This invention provides an ADNF polypeptide comprising an active core site, the active core site comprising at least one D-amino acid. The invention also provides a pharmaceutical composition comprising an ADNF polypeptide comprising an active core site, the active core site comprising at least one D-amino acid. In particular, the pharmaceutical composition of the invention is orally active. The invention further provides methods for reducing neuronal cell death, methods for reducing oxidative stress, and methods for reducing a condition associated with fetal alcohol syndrome using the ADNF polypeptides and the pharmaceutical compositions of the invention.
    Type: Grant
    Filed: August 17, 2000
    Date of Patent: June 10, 2008
    Assignee: National Institute of Health
    Inventors: Douglas E. Brenneman, Catherine Y. Spong, Illana Gozes, Albert Pinhasov, Eliezer Giladi
  • Patent number: 7264947
    Abstract: The present invention relates generally to Activity Dependent Neurotrophic Factor III (ADNF III), also known as Activity Dependent Neuroprotective Protein (ADNP). More particularly, the present invention relates to nucleic acid sequences encoding ADNF III polypeptides; ADNF III polypeptides encoded by such nucleic acid sequences; antibodies to ADNF III polypeptides; and methods of using such ADNF III polypeptides for the treatment of neurological deficiencies and for the prevention of cell death associated with (1) gp120, the envelope protein from HIV; (2) N-methyl-D-aspartic acid (excito-toxicity); (3) tetrodotoxin (blockage of electrical activity); and (4) ?-amyloid peptide, a substance related to neuronal degeneration in Alzheimer's disease.
    Type: Grant
    Filed: July 17, 2003
    Date of Patent: September 4, 2007
    Assignee: United States of America, as represented by the Secretary of the Department of Health and Human Services
    Inventors: Illana Gozes, Douglas E. Brenneman, Merav Bassan, Rachel Zamostiano
  • Patent number: 6933277
    Abstract: This invention relates to a method for reducing a condition associated with fetal alcohol syndrome in a subject who is exposed to alcohol in utero with an ADNF polypeptide. In particular, the present invention relates to a method of reducing a condition associated with fetal alcohol syndrome in a subject who is exposed to alcohol in utero with a combination of ADNF I and ADNF III polypeptides. The present invention further relates to a method for reducing neuronal cell death by contacting neuronal cells with a combination of ADNF I and ADNF III polypeptides. Still further, the present invention relates to a pharmaceutical composition comprising a combination of ADNF I and ADNF III polypeptides.
    Type: Grant
    Filed: March 12, 1999
    Date of Patent: August 23, 2005
    Assignees: The United States of America as represented by the Department of Health and Human Services, Ramot University Authority for Applied Research and Industrial Development, Ltd.
    Inventors: Douglas E. Brenneman, Catherine Y. Spong, Illana Gozes, Merav Bassan, Rachel Zamostiano
  • Publication number: 20040235747
    Abstract: The present invention provides methods for preventing and/or treating autoimmune diseases, including multiple sclerosis, in a subject using ADNF polypeptides, by treating the subject with an Activity Dependent Neurotrophic Factor (ADNF) polypeptide.
    Type: Application
    Filed: December 29, 2003
    Publication date: November 25, 2004
    Applicants: Ramot At Tel-Aviv University Ltd., The Govt. of the USA as represented by the Secretary of the Dept. of Health & Human Services
    Inventors: Illana Gozes, Daniel Offen, Eliezer Giladi, Eldad Melamed, Douglas E. Brenneman
  • Publication number: 20040053313
    Abstract: The present invention relates generally to Activity Dependent Neurotrophic Factor III (ADNF III), also known as Activity Dependent Neuroprotective Protein (ADNP). More particularly, the present invention relates to nucleic acid sequences encoding ADNF III polypeptides; ADNF III polypeptides encoded by such nucleic acid sequences; antibodies to ADNF III polypeptides; and methods of using such ADNF III polypeptides for the treatment of neurological deficiencies and for the prevention of cell death associated with (1) gp120, the envelope protein from HIV; (2) N-methyl-D-aspartic acid (excito-toxicity); (3) tetrodotoxin (blockage of electrical activity); and (4) &bgr;-amyloid peptide, a substance related to neuronal degeneration in Alzheimer's disease.
    Type: Application
    Filed: July 17, 2003
    Publication date: March 18, 2004
    Applicants: The Government of the USA as Represented by the Secretary of the Dept. of Health & Human Services, Ramot University Authority for Applied Research and Industrial Development, Ltd.
    Inventors: Illana Gozes, Douglas E. Brenneman, Merav Bassan, Rachel Zamostiano
  • Patent number: 6649411
    Abstract: The present invention provides methods of using antisense ADNF III oligonucleotides to inhibit the growth of pathologically proliferating cells. The invention also provides methods and kits for using ADNF III nucleic acid probes to detect the presence of pathologically proliferating cells in human tissues.
    Type: Grant
    Filed: July 30, 1999
    Date of Patent: November 18, 2003
    Assignees: The United States of America as represented by the Department of Health and Human Services, Ramot at Tel-Aviv University Ltd.
    Inventors: Illana Gozes, Douglas E. Brenneman, Rachel Zamostiano, Edgar Gelber, Albert Pinhasov, Merav Bassan
  • Patent number: 6613740
    Abstract: The present invention relates generally to Activity Dependent Neurotrophic Factor III (ADNF III), also known as Activity Dependent Neuroprotective Protein (ADNP). More particularly, the present invention relates to nucleic acid sequences encoding ADNF III polypeptides; ADNF III polypeptides encoded by such nucleic acid sequences; antibodies to ADNF III polypeptides; and methods of using such ADNF III polypeptides for the treatment of neurological deficiencies and for the prevention of cell death associated with (1) gp120, the envelope protein from HIV; (2) N-methyl-D-aspartic acid (excito-toxicity); (3) tetrodotoxin (blockage of electrical activity); and (4) &bgr;-amyloid peptide, a substance related to neuronal degeneration in Alzheimer's disease.
    Type: Grant
    Filed: November 6, 1998
    Date of Patent: September 2, 2003
    Assignees: Ramot University Authority for Applied Research and Industrial Development Ltd., The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Illana Gozes, Douglas E. Brenneman, Merav Bassan, Rachel Zamostiano
  • Publication number: 20030036521
    Abstract: The present invention provides methods of using antisense ADNF III oligonucleotides to inhibit the growth of pathologically proliferating cells. The invention also provides methods and kits for using ADNF III nucleic acid probes to detect the presence of pathologically proliferating cells in human tissues.
    Type: Application
    Filed: July 30, 1999
    Publication date: February 20, 2003
    Inventors: ILLANA GOZES, DOUGLAS E. BRENNEMAN, RACHEL ZAMOSTIANO, EDGAR GELBER, ALBERT PINHASOV, MERAV BASSAN